Clinical Trial Update: Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating dose escalation of Octreotide-LAR as first-line therapy in resistant acromegaly; the study is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Octreotide LAR (octreotide long-acting release)

Snippet

Sponsor: Federico II University | Conditions: Acromegaly | Phase 4 | Status: COMPLETED